Reuters logo
in 6 months
BRIEF-Global Blood Therapeutics reports initiation of phase 1 trial to evaluate the physiologic effects of GBT440
February 16, 2017 / 9:31 PM / in 6 months

BRIEF-Global Blood Therapeutics reports initiation of phase 1 trial to evaluate the physiologic effects of GBT440

Feb 16 (Reuters) - Global Blood Therapeutics Inc :

* Global Blood Therapeutics announces initiation of phase 1 trial to evaluate the physiologic effects of gbt440 in healthy volunteers under hypoxemic conditions

* Global Blood Therapeutics -currently conducting 2 phase 2a clinical trials of gbt440 as potential treatment for hypoxemia in 2 groups of hypoxemic ipf patients Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below